http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/issue/feedJURNAL ILMU KEFARMASIAN INDONESIA2024-01-24T06:18:17+00:00Shirly Kumalaadminjifi@univpancasila.ac.idOpen Journal Systems<p style="text-align: justify;"><strong><span style="font-weight: 400;">The Indonesian Journal of Pharmaceutical Sciences, or JIFI (Jurnal Ilmu Kefarmasian Indonesia), ISSN (</span><span style="font-weight: 400;">p-ISSN:</span><a href="https://issn.brin.go.id/terbit/detail/1180428524"><span style="font-weight: 400;">1693-1831</span></a><span style="font-weight: 400;">, e-ISSN: </span><a href="https://issn.brin.go.id/terbit/detail/1511839542"><span style="font-weight: 400;">2614-6495</span></a><span style="font-weight: 400;">), is a scientific journal published by the Faculty of Pharmacy, Universitas Pancasila, Jakarta. JIFI has been publishing since 2003, twice a year in April and October. JIFI was first accredited in 2007 in accordance with the decree of DIKTI No. 167/DIKTI/KEP/2007 with predicate B. Based on the 2</span><span style="font-weight: 400;">nd</span><span style="font-weight: 400;"> Scientific Periodical Accreditation in 2013, JIFI was set as accredited Periodical Scientific Issues by decree of the Minister of Education and Culture of Republic Indonesia No. 040/P/2014 on February 14, 2014. In 2019, JIfI has been accredited SINTA 2, as quoted from the decision of the Director General of RISTEKDIKTI in the 7</span><span style="font-weight: 400;">th</span><span style="font-weight: 400;"> Scientific Periodical Journal Accreditation with decree No. 36/E/KPT/2019 on December 13, 2019. Since September 2023, the journal has collaborated with PAFI (Persatuan Ahli Farmasi Indonesia, or Indonesian Pharmacy Experts Association) <a href="https://drive.google.com/file/d/1kpZCNEoh567lVff2dOumwXPk3jq52X36/view">No. 036/FF-UP/PKS-PAFI/IX/2023</a> and only receives manuscripts in English.</span></strong></p> <p style="text-align: justify;"><br>JIFI loads selected articles from research results and a literature review based on pharmaceutical sciences. The article comes from authors who are affiliated with the university, the research and development department, a non-departmental government agency, or other institutions that are active in pharmaceutical research, science, and technology. Manuscripts received by editors at JIFI will be reviewed and selected by peer reviewers and the editorial board according to their field expertise.</p>http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1547 Content2024-01-24T06:18:17+00:00- -adminjifi@univpancasila.ac.id<p>--</p>2023-10-31T00:00:00+00:00##submission.copyrightStatement##http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1481 Cosmos caudatus Kunth. Leaf Extract Herbal Nanosuspension Formulations, Characterization, and Cytotoxicity Approach Against MCF-7 Breast Cancer Cells2023-11-20T02:12:33+00:00Safira Nafisasafira.nafisa@univpancasila.ac.idSiti Umrah Noorsiti_umrahnoor@yahoo.comAzkannufuus Azkannufuussafira.nafisa@univpancasila.ac.idYuslia Novianisafira.nafisa@univpancasila.ac.id<p>Kenikir leaves (Cosmos caudatus Kunth.) contain quercetin, which has anticancer properties. To provide more effective complementary therapy for breast cancer, nanotechnology was applied to develop preparations containing kenikir leaf extract. This research aimed to formulate a nanosuspension containing kenikir leaf extract with cytotoxic activity against MCF-7 breast cancer cells. Nanosuspension of kenikir leaf extract was prepared using the ionic gelation method with 3%, 4%, and 5% PVP K-30 stabilizer. The nanosuspension formula with the highest entrapment efficiency was further characterised, including particle size, polydispersity index (PDI), zeta potential, pH, and particle morphology. Cytotoxic activity was tested against MCF-7 cells by the MTT assay. The results showed that the formula with 5% PVP has the highest entrapment efficiency value of 85.04±0.08%, a particle size of 221.9 nm, a PDI of 0.211, a zeta potential of -21.7 mV, a pH of 4.08±0.0, and a spherical morphology. The kenikir leaf extract at a concentration of 1 mg/mL inhibited the proliferation of MCF-7 cells by 23.4% (p<0.05), whereas the nanosuspension at 10 μg/mL inhibited proliferation by 23.7%. It can be concluded that kenikir leaf extract can be formulated into a nanosuspension that meets the physical criteria and has cytotoxic activity against MCF-7 cells.</p>2023-10-27T15:35:55+00:00##submission.copyrightStatement##http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1484 Drug Selection, Dosage Adjustment, and Potential Interaction of Antihypertensive and Antidiabetic for Chronic Kidney Disease with Hemodialysis2023-11-14T07:06:04+00:00Nisa Mariafvidyananda@gmail.comFerlina Vidyananda Susilofvidyananda@gmail.comMayannaria Simarmatafvidyananda@gmail.com<p>Antihypertensive and antidiabetic drugs in CKD patients on hemodialysis may cause medication-related problems requiring monitoring. This study aimed to evaluate the selection, dosage, and potential drug interactions of antihypertensive and antidiabetic drugs in stage 5 CKD patients with hypertension and/or type 2 diabetes mellitus undergoing hemodialysis in a hospital in Jakarta. A crosssectional study used the medical records of adult in patients from January - December 2022 with a total sampling method. Out of 101 patients, 97.0% received appropriate drug selection. Dosage adjustments were appropriate in 74.3% of cases. Potential drug interactions between antihypertensive and antidiabetic drugs were found in 90.1% of patients, mostly pharmacodynamic interactions, moderate severity, and requiring monitoring. Statistical analysis showed that age, gender, number of drugs, and length of stay were not associated with the appropriateness of antihypertensive and antidiabetic drug selection (p>0.05). However, there was a relationship between number of drugs (p=0.033; OR=2.996) and length of stay (p=0.024; OR=3.171) with the appropriateness of drug dosage. The length of stay was also associated with potential drug interactions (p=0.040; OR=8.426). Drug selection has been done well, but there is a need for improvement in monitoring dosage adjustments and potential drug interactions by pharmacists in the hospital.</p>2023-10-25T00:00:00+00:00##submission.copyrightStatement##http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1487 Education and Training for Improving Pharmacist’s Telepharmacy Competencies: A Scoping Review2023-11-20T02:06:15+00:00Kartika Citra Dewi Permata Sarinadia.farhanah@farmasi.ui.ac.idNisa Marianadia.farhanah@farmasi.ui.ac.idLarasati Arrum Kusumawardaninadia.farhanah@farmasi.ui.ac.idHindun Wilda Risninadia.farhanah@farmasi.ui.ac.idNadia Farhanah Syafhannadia.farhanah@farmasi.ui.ac.idAfina Nur Fauziyyahafina.fauziyyah.21@ucl.ac.uk<p>Antihypertensive and antidiabetic drugs in chronic kidney disease (CKD) patients undergoing hemodialyThe high demand for telepharmacy services led to the urge for proper training and education to enhance its quality. This review aimed to assess the implementation and outcomes of telepharmacy training and education programmes. This scoping review was conducted on ScienceDirect, Sage Journal, SpringerLink, and Google Scholar databases using keywords “training” OR “education” AND “telepharmacy,” “training” OR “education” AND “digital competency” AND “pharmacy.” Only English-written articles published between 2000 – 2023, original research and brief report were included in this review. Eight of 171 articles met the criteria and the study’s objectives. Those studies discussed telepharmacy learning programmes for pharmacy students in the USA (5 articles), UAE (2 articles), and Malaysia (1 article). The learning methods included didactic learning, case-based study, simulation/roleplay, and clerkship employing technological tools. Rubrics, quizzes, questionnaires, and objective structured clinical examination (OSCE) were used as assessment methods. All studies reported improved students’ knowledge, perceptions, and telepharmacy competencies. In conclusion, the telepharmacy learning programmes have effectively upgraded students’ knowledge and skills by various methods at every level. However, there remains a considerable need for evidence on suitable training for pharmacists to improve their telepharmacy competencies and service quality.</p>2023-10-25T00:00:00+00:00##submission.copyrightStatement##http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1406 Optimization of Fast Disintegrating Tablets Diphenhydramine HCl using Co-process of Cross-link Yellow Kepok Banana Starch, Crospovidone, and Microcrystalline Cellulose2023-11-14T03:53:46+00:00Tias Eka Rahmawatitiasekarahmawati@gmail.comAgus Siswantosiswanto.kpp@gmail.comAsmiyenti Djaliasrin Djalilasmiyenti@gmail.com<p>Diphenhydramine HCl is an antihistamine drug that is available in conventional tablet form. This study aimed to produce the optimum formula for a diphenhydramine fast disintegrating tablet (FDT) using a modification of starch, crospovidone, and microcrystalline cellulose (MCC) to produce quality tablets that meet the tablet's physical requirements and tablet dissolution. Starch modification was made using a two-step method of starch cross-link, then continued with silica coprecipitation. FDT was prepared by the direct compression method. Optimisation with the simplex lattice design (SLD) model uses three components: co-process starch crosslink-silica, crospovidone, and MCC, which obtained 14 formula designs. The hardness, wetting time, disintegration time, and percent dissolution are optimisation parameters. Equations, contour plots, and desirability values were determined as the optimum formula. Based on the research results, an optimum formula was obtained with the proportion of co-process cross-link starch-silica was 56.185 mg, crospovidone at 6 mg, and MCC at 45.815 mg. The result of hardness was 5 kg, wetting time 51.061 seconds, disintegration time 63.129 seconds, and dissolution was 100.972%. The interaction of the three components reduces hardness and increases disintegration time, wetting time, and percent dissolution.</p>2023-10-19T00:00:00+00:00##submission.copyrightStatement##